UCLA researchers have developed a novel therapy that could fundamentally change the treatment plan for triple-negative breast cancer, one of the most aggressive cancers. “Patients with triple-negative breast cancer have been waiting far too long for better treatment options,” said senior author Dr. Lili Yang. “To finally have a therapy that shows superior cancer-fighting ability — and to be just one step away from clinical testing — is incredibly exciting.” #ResearchPowersProgress ➡️ https://bit.ly/47jLomR
UCLA researchers develop promising therapy for triple-negative breast cancer
This title was summarized by AI from the post below.
More Relevant Posts
-
Breast cancer is not one disease—and not all subtypes respond the same. In our latest article, we break down how molecular testing applies across TNBC, HER2+, and triple positive breast cancer, including how Northstar Select® and Northstar Response® support real-time, subtype-specific decisions. Read it here: https://lnkd.in/ggi3agtA #BreastCancerAwareness #NorthstarOncology #TNBC #HER2 #TriplePositive #LiquidBiopsy #PrecisionOncology #CGP #ClinicalUtility
-
-
In the past decade, breast cancer treatments have exponentially improved. Thanks to clinical trials and the patients who join them, treatments today are more personalized, less invasive, and more effective than ever. Every breakthrough—from targeted therapies to immunotherapy—started with a clinical trial. If you or a loved one is facing breast cancer, exploring clinical trials can be an empowering step. Together, patients and researchers are turning today’s trials into tomorrow’s triumphs. Read the full blog here: https://lnkd.in/e82E-yFn #BreastCancerAwareness #ClinicalResearch #ClinicalTrials
-
-
An 11% increase in pCR — but is it enough to predict long-term benefit? Drs. Pegram and Neil Iyengar explore whether DESTINY-Breast11’s results will translate into durable survival gains for HER2+ early-stage breast cancer. 👉 Watch more oncology conversations and listen to the full episode on your preferred streaming platform https://lnkd.in/eWm-bdNw #TDXd #BreastCancer #HER2Positive #DB11 #pCR #ESMO2025 #OncologyPodcast #CancerResearch
-
🩺 Colorectal Cancer Screening: What Women Over 40 Need to Know Colorectal cancer is highly treatable when detected early. Our infographic outlines the screening process and key considerations for women in this age group. 👉 Learn more in the full guide: https://lnkd.in/gAYq37yg #ColorectalCancer #Screening #WomensHealth #CancerPrevention #AJPHI
-
-
In just the last decade, 18 new breast cancer treatments have been FDA-approved thanks to clinical findings from BCRF investigators and others. Every breakthrough brings us closer to better outcomes, more options, and a future without breast cancer. This is the power of research. Explore the full timeline of research breakthroughs here: https://lnkd.in/eMkuWKGy
-
-
Results from the phase 2 #AMALEE trial demonstrate that a 400 mg starting dose of #ribociclib, when combined with a nonsteroidal aromatase inhibitor, reduced the incidence of dose-dependent adverse events while maintaining comparable efficacy to the standard 600 mg dose among patients with HR-positive, HER2-negative advanced breast cancer. Learn more: https://lnkd.in/eafTnEYM
-
-
🎀 Breast Cancer Screening: When & How You Should Start For women over 40, timely breast cancer screening—such as mammograms, clinical exams, and self‑awareness—can make all the difference in early detection and survival. This infographic breaks down the recommended ages, methods, and screening frequency. 👉 Read the full guide by Dr. Rawal & Dr. Thapa: https://lnkd.in/gAYq37yg #BreastCancer #CancerScreening #WomensHealth #PreventiveCare #AJPHI
-
-
Memorial Sloan Kettering Cancer Center (MSK) presented two breakthrough therapies at the 2025 American Society of Cancer Oncology (ASCO) Annual Meeting that are important for employers to know about. These treatments show meaningful survival improvements for patients with ER+/HER2- advanced breast cancer, the most common subtype, accounting for about 70% of cases. For employers specifically, more effective, earlier treatment can reduce downstream costs and improve quality of life—something every employer should care about. Learn more about how MSK Direct can help with benefits strategies: https://bit.ly/3WcMCv9
-
-
October is National #BreastCancerAwarenessMonth. The Alliance is dedicated to advancing research in breast cancer screening and treatment to expand access to evidence-based care and improve outcomes for all patients. Currently, Alliance has six clinical trials active with a focus on breast cancer. To learn more about these trials, visit https://ow.ly/EjWV50Xen1F. #NCI #NCTN #CancerResearch
-
-
We met with BCRF investigator Dr. Neil Iyengar to share key findings coming out of #ESMO25, an annual meeting in Europe dedicated to advancing cancer research and treatment. He breaks down the biggest updates in hormone receptor–positive breast cancer, including what these discoveries could mean for patients and the future of care.
Berkeley Chemical Biology × Brandeis Bioinformatics.
4wUCLA's development of a novel therapy for triple-negative breast cancer (TNBC) is an important step forward. However, I'm wrestling with the broad claim of "superior cancer-fighting ability" and being "just one step away from clinical testing." The inherent molecular and clinical heterogeneity of TNBC presents a significant barrier to such generalizations. Several studies, including a 2022 review, emphasize that TNBC comprises at least four major biologically distinct subtypes, complicating the development of universally effective targeted therapies and often limiting efficacy to a small portion of patients. Moreover, a frequent challenge in this field is the disconnection between promising preclinical results—often derived from simplified models—and their translation to diverse patient populations in clinical trials. Given this, what specific preclinical data supports the "superior" efficacy across the known molecular subtypes of TNBC, and what strategies are in place to address the anticipated variable responses in a heterogeneous patient cohort during clinical trials?